Combination Endocrine Therapy in the Management of Breast Cancer

Combination Endocrine Therapy in the Management of Breast Cancer Laura Boehnke Michaud, Kellie L. Jones, Aman U. Buzdar Oncologist 2001; 6: 538-546. Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Identify the role of combination endocrine therapy in the treatment of breast cancer. Understand pharmacokinetic interactions between aromatase inhibitors and antiestrogens. Discuss data using LHRH agonists in combination with aromatase inhibitors. Identify the role of LHRH agonists with antiestrogens in both metastatic and early breast cancer. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Feb. 13, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Apr. 9, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.